Financhill
Back

Orgenesis Quote, Financials, Valuation and Earnings

Orgenesis Price Quote

$1.20
-0.03 (-2.04%)
(Updated: October 31, 2024 at 6:55 PM ET)

Orgenesis Key Stats

Sell
3
Orgenesis (ORGS) is a Sell

Day range:
$1.12 - $1.27
52-week range:
$1.03 - $10.80
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
5.83
P/B ratio:
0%

Volume:
15.9K
Avg. volume:
61.9K
1-year change:
-84.88%
Market cap:
$5.6M
Revenue:
$530K
EPS:
$-8.5

How Much Does Orgenesis Make?

  • How Much Are Orgenesis's Sales Annually?
    ORGS Revenues are $530K
  • How Much Profit Does Orgenesis's Make A Year?
    ORGS net income is -$55.4M

Is Orgenesis Growing As A Company?

  • What Is Orgenesis's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 1.18%
  • What Is Orgenesis's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Orgenesis Stock Price Performance

  • Did Orgenesis Stock Go Up Last Month?
    Orgenesis share price went down by -72.53% last month
  • Did ORGS's Share Price Rise Over The Last Year?
    ORGS share price fell by -84.88% over the past 1 year

What Is Orgenesis 52-Week High & Low?

  • What Is Orgenesis’s 52-Week High Share Price?
    Orgenesis has traded as high as $10.80 over the past 52 weeks
  • What Is Orgenesis’s 52-Week Low Share Price?
    Orgenesis has traded as low as $1.03 over the past 52 weeks

Orgenesis Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Orgenesis?

  • How Much Debt Does Orgenesis Have?
    Total long term debt quarterly is $11.2M
  • How Much Cash Does Orgenesis Have?
    Cash and short term investments quarterly total is $77K
  • What Is Orgenesis’s Book Value Per Share?
    Book value per share is -3.30

Is Orgenesis Cash Flow Positive?

  • What Is ORGS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$12M
  • What Is Orgenesis’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $12.9M
  • What Is Orgenesis’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$974K

Orgenesis Return On Invested Capital

  • Is Management Doing A Good Job?
    ORGS return on invested capital is -198.63%
  • What Is Orgenesis Return On Assets?
    ROA measures how assets are converting to revenues and is -82.38%
  • What Is ORGS Return On Equity?
    ROE is a measure of profitability and is 0%

Orgenesis Earnings Date & Stock Price

  • What Is Orgenesis's Stock Price Today?
    A single share of ORGS can be purchased today for 1.23
  • What Is Orgenesis’s Stock Symbol?
    Orgenesis trades on the otcm under the ticker symbol: ORGS
  • When Is Orgenesis’s Next Earnings Date?
    The next quarterly earnings date for Orgenesis is scheduled on November 13, 2024
  • When Is ORGS's next ex-dividend date?
    Orgenesis's next ex-dividend date is November 1, 2024
  • How To Buy Orgenesis Stock?
    You can buy Orgenesis shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Orgenesis Competitors

  • Who Are Orgenesis's Competitors?
    Below is a list of companies who compete with Orgenesis or are related in some way:
    • Cormedix Inc (CRMD)
    • Intuitive Surgical Inc (ISRG)
    • Eli Lilly and Co (LLY)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Catheter Precision Inc (VTAK)

Orgenesis Dividend Yield

  • What Is ORGS Dividend Yield?
    Orgenesis’s dividend yield currently is 0%
  • What Is Orgenesis’s Payout Ratio?
    Orgenesis’s payout ratio is 0%
  • When Did Orgenesis Last Pay A Dividend?
    The latest dividend pay date is November 1, 2024
  • What Is Orgenesis’s Dividend Per Share?
    Orgenesis pays a dividend of $0.00 per share

Orgenesis Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -530%
Revenue: 117.7% -99.19%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 60.00
Upside from Last Price: 4797.96%

Major Shareholders

  • How many ORGS shares are owned by institutional investors?
    1.9M ORGS shares are owned by institutional investors
  • How many ORGS shares are owned by insiders?
    2.3M ORGS shares are owned by insiders